D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering
HWH International Inc. is a purpose-driven lifestyle company encompassing differentiated offerings from four core pillars: Hapi Marketplace, Hapi Cafe, Hapi Travel and Hapi Wealth Builder. The Company ...
Hosted on MSN14h
D. Boral Capital Initiates Coverage of Nano-X Imaging (NNOX) with Buy Recommendation
Fintel reports that on January 6, 2025, D. Boral Capital initiated coverage of Nano-X Imaging (NasdaqGM:NNOX) with a Buy ...
Nano-X Imaging initiated with a Buy at D. Boral Capital
D. Boral Capital analyst Jason Kolbert initiated coverage of Nano-X Imaging (NNOX) with a Buy rating and $23 price target Nanox is at the ...
D. Boral Capital Cuts Pineapple Financial (NYSEAMERICAN:PAPL) Price Target to $5.00
Pineapple Financial (NYSEAMERICAN:PAPL – Get Free Report) had its price target dropped by analysts at D. Boral Capital from $5.50 to $5.00 in a research note issued on Monday,Benzinga reports. The ...
CytoSorbents reported strong Q4 results, says D. Boral Capital
D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% ...
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital
D. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on ...
Hosted on MSN14d
D. Boral Capital Initiates Coverage of Omeros (OMER) with Buy Recommendation
Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a ...
Boral Capital将Nano-X Imaging股票评级设为买入，看好其创新
周一，Boral Capital对Nano-X Imaging（NASDAQ:NNOX）股票启动覆盖，给予买入评级，目标价为$23.00。该公司分析师强调了Nano-X在医学影像领域的创新方法，突出其Nanox.ARC技术在该领域的革命性作用。
manilatimes26d
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
BTIG and H.C. Wainwright & Co. are acting as co-lead managers with D. Boral Capital acting as co-manager for the offering. This press release shall not constitute an offer to sell or the solicitation ...
Morningstar19d
D. Boral Capital Acted as Exclusive Placement Agent to Webuy Global Ltd (Nasdaq: WBUY) in connection with its $3.7 Million Registered Direct Offering
D. Boral Capital LLC acted as the exclusive placement agent for the offering. Ortoli Rosenstadt LLP acted as counsel to the Company and Hunter Taubman Fischer & Li LLC acted as counsel to D.
D. Boral Capital开始对Avita Medical股票进行覆盖，引用美国市场渗透率
D. Boral Capital的分析师强调了Recell有潜力为一系列产品铺平道路，如PermeaDerm和Cohealyx，这些产品旨在管理全方位的软组织和深层组织护理。这一潜力得到了公司在过去十二个月中32.24%的收入增长和85.66%的强劲毛利率的支持。Avita Medical在美国的市场渗透是该公司模型的主要焦点，并预期会进一步扩大市场。